IL-13Rα2, also known as CD213A2 and cancer/testis antigen 19 (CT19), is a glycosylated transmembrane protein which is highly expressed in several cancer types including glioblastoma,87 breast cancer,88 ovarian carcinoma,89 and colorectal cancer.90 It has been successfully applied as a therapeutic target of chimeric antigen receptor (CAR)-engineered T cells in a patient with recurrent multifocal glioblastoma.91 IL-13Rα2 has a short cytoplasmic motif that lacks the conserved box 1 region necessary for signal transduction. This evidence concerns the gene IL13RA1 and glioblastoma.